Vendor: Marketplace supplier
Product metadata will be available once the catalog entry is complete.
Formulations: - Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection Indications: - Congenital syphilis [children] - Syphilis Source: EML workbook import
Formulations: - Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt) Indications: - Osteomyelitis or osteitis - Bacterial infection of joint - Bacterial cellulitis, erysipelas or lymphangitis - Sepsis without septic shock - Bacterial infection of unspecified site Alternatives: - amikacin Source: EML workbook import
Formulations: - Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous) Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate) Parenteral > General injections > unspecified: 100 mg in vial powder for injection Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium) Oral > Solid > dispersible tablet: 100 mg (as monohydrate) Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate) Oral > Solid > dosage form: 100 mg (as hyclate) - Oral > Solid: 100 mg (hydrochloride or hyclate) - Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid Oral > Solid > dispersible tablet: 100 mg (as monohydrate) Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate) - Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate) Indications: - Cholera - Chlamydia trachomatis - Cholera [children] - Chronic obstructive pulmonary disease with acute exacerbation - Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) - Bacterial infection of unspecified site - Malaria due to Plasmodium falciparum Source: EML workbook import
Formulations: - Oral > Liquid: 25 mg per 5 mL oral liquid Oral > Solid > dosage form: 100 mg; 50 mg Indications: - Infectious cystitis Source: EML workbook import
Formulations: - Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid Oral > Solid: 250 mg (as potassium salt) tablet Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt) Indications: - Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) - Periapical abscess without sinus - Acute pharyngitis - Bacterial infection of unspecified site Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule Oral > Solid > dispersible tablet: 100 mg + 20 mg - Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet Oral > Solid > dispersible tablet: 100 mg + 20 mg Indications: - Infectious cystitis - Infectious gastroenteritis or colitis without specification of infectious agent - Bacterial infection of unspecified site - Pneumocystosis Source: EML workbook import
Ready to amplify your rewards? Drop your email and we'll be in touch soon.
